Srdan Verstovsek, MD, of the University of Texas MD Anderson Cancer Center discusses the phase III VERIFY trial of the hepcidin mimetic rusfertide in patients with polycythemia vera.
Srdan Verstovsek, MD, on the Phase III VERIFY Trial
By Leah Sherwood, Srdan Verstovsek, MD, PhD - Last Updated: May 30, 2023Post Tags:ASH22
Related Posts
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
Side effects are an important consideration when using bispecific antibodies in this population, Dr. Krina Patel explains.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
Dr. Krina Patel was part of a comparative study team which evaluated these two therapies' efficacy and safety in MM care.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.